Vaxcyte, Inc.

PCVX Nasdaq SEC CIK 1649094
Follow Vaxcyte Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$297.1M −39.6% vs same quarter last year
EPS, diluted −$1.99 −27.6% vs same quarter last year
Operating cash flow −$224.1M −56.4% vs same quarter last year
Operating income −$308.3M −27.2% vs same quarter last year
Net income by quarter
$326.4M
−$140.7M
−$166.6M
−$212.8M
$519.4M
−$320.6M
−$284.3M
−$297.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$100M−$75M−$50M−$25M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$766.6K
FY24−$463.9K
FY23−$402.3K
FY22−$223.5K
FY21−$100.1K
FY20−$89.2M
FY19−$50.3M
FY18−$29.5M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$800M−$600M−$400M−$200M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$669.3M
FY24−$475.1M
FY23−$312.9M
FY22−$176.4M
FY21−$127.9M
FY20−$47.8M
FY19−$48.3M
FY18−$32.2M
FY17-